Automated Insulin Delivery Systems Market

Automated Insulin Delivery Systems Market: Introduction

• Automated Insulin Delivery Systems (AIDS) are advanced medical devices that aid in the management of blood glucose levels of patients with diabetes. The systems automate the task of insulin delivery, which is meant to imitate the action of a healthy functional pancreas by continuously monitoring the glucose level and delivering insulin when needed.
• The aim is to deliver maximum glucose control using minimal user input. AIDS are found to be particularly helpful for individuals who have Type 1 diabetes, where the pancreas does not produce insulin, and Type 2 diabetes, particularly for patients who have difficulty maintaining a level of glucose content despite conventional treatment with insulin.
• The primary elements of an automated insulin delivery systems are usually an insulin pump, a continuous glucose monitor (CGM), and an algorithm that utilizes data from the CGM to calculate insulin requirements. The insulin pump administers insulin via a catheter inserted under the skin.
• The CGM monitors the user's blood glucose continuously with real-time results. The algorithm of the system subsequently computes this data and automatically regulates the insulin infusion to keep the blood glucose in a range. Current systems are constructed so as to carry out most of the work involved in delivering insulin automatically, providing an advanced level of diabetes control with minimal effort by the patient.
• The primary advantage of automated insulin delivery systems is improved glycemic control. With the delivery of insulin being automated according to real-time glucose levels, these systems can minimize blood glucose variability thereby lowering the risk of hyperglycemia as well as hypoglycemia. This results in improved overall diabetic control and may decrease the likelihood of long-term complications like cardiovascular disease, neuropathy, and retinopathy. These systems also provide more convenience and autonomy to patients as they involve less hands-on management than insulin therapy.
• Recent technological developments in automated insulin infusion systems have made them far more efficient and user-friendly. For instance, newer models have used more advanced algorithms, which increase the accuracy and responsiveness of insulin infusion. The algorithms are able to modify insulin infusion in real-time according to glucose trend, insulin sensitivity, and activity. Additionally, advancements in smartphone connectivity and cloud-based tracking of data have made it possible for healthcare providers and patients to track glucose trends and insulin infusion remotely.

Rising Prevalence of Diabetes is Fueling the Global Automated Insulin Delivery Systems Market

• Increase in prevalence of diabetes is the primary driver to the automated insulin delivery systems (AIDS) market. The incidence of type 1 and type 2 diabetes is rising at a high rate worldwide. As such, demand for more advanced insulin delivery systems has increased manifold.
• The burden of diabetes has increased over the years, with the International Diabetes Federation (IDF) estimating that more than 400 million individuals globally have diabetes, and this trend is likely to increase exponentially in the next few decades. As the diabetic population is growing, the demand for advanced insulin delivery systems is also growing, which is bound to provide more precise, effective, and convenient means of glucose control, which are important for the improvement of the quality of life as well as for prevention of complications.
• Diabetes care involves regular monitoring of blood glucose and accurate administration of insulin. Conventionally, insulin administration has been accomplished via injections or shots several times a day, which is exhausting and difficult for patients to do.
• With growing diabetes patient population, healthcare systems across the globe are focusing on personalized medicine. Diabetes patients need customized treatment regimens based on their specific glucose profiles, lifestyle, food intake, and physical activity level. Automated insulin delivery systems are best fitted for personalized treatment since they link data from continuous glucose monitoring sensors and adjust insulin delivery in real-time according to the individual requirements of the patient.

Technological Advancements in Insulin Delivery Systems Bolstering the Expansion of Global Automated Insulin Delivery Systems Market

• Advancements in insulin delivery algorithms in the recent past have improved the responsiveness and precision of automated insulin delivery systems. These algorithms calculate real-time glucose levels from CGMs and determine the optimal insulin dose as one of the functions of insulin sensitivity, glucose trend, meal, and activity.
• Development of adaptive algorithms translates into insulin delivery systems getting more intelligent and learning how the user handles the condition, thereby improving treatment along the way.
• The evolution of technology has resulted in the invention of hybrid and completely closed-loop insulin delivery systems. In a closed-loop hybrid system, the insulin pump and CGM not only join hands to provide automated insulin delivery for basal (background) rates but also require the user to administer bolus doses prior to meals or adjustments for certain events.
• The shape and size of insulin pumps have also changed significantly in recent years. With advancements in technology through miniaturization and user-friendliness, pumps have turned out to be smaller and more stealth-like, thereby being more wearable and convenient for the daily use.

North America to Lead Automated Insulin Delivery Systems Market

• In terms of region, the global automated insulin delivery systems market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
• North America is anticipated to dominate the global automated insulin delivery systems industry throughout the forecast period due to several key factors that support the widespread adoption and growth of these technologies in the region.
• North America has one of the highest prevalence rates of diabetes in the world. According to the Centers for Disease Control and Prevention (CDC), in 2021, more than 38.4 million Americans have diabetes, constituting 11.6% of the U.S. population, while millions more are anticipated to be undiagnosed. This high prevalence creates a significant demand for delivery solutions

Key Players Operating in Global Automated Insulin Delivery Systems Market

The major players operating in the global market are focusing on technological advancements and expansions to meet the rising demand for automated insulin delivery systems.

Key players operating in the global automated insulin delivery systems market include:

• Medtronic
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Beta Bionics
• Diabeloop SA
• F. Hoffmann-La Roche Ltd
• Dexcom, Inc.
• Abbott

Automated Insulin Delivery Systems Market Segmentation

• By Product Type:
  • Predictive Low Glucose Suspend (PLGS) System
  • Hybrid Closed Loop (HCL) / Advanced Hybrid Closed Loop (AHCL) System
  • Fully Closed Loop (FCL) System
• By Diabetes Type:
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Patient Age Group:
  • Pediatric
  • Adult
  • Geriatric
• By End-user:
  • Hospitals and Clinics
  • Homecare Settings
  • Others
• By Region:
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa